• M Xiao, C Lou, H Xiao, Y Yang, X Cai, C Li, S Jia, and Y Huang.
• Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
• Br J Surg. 2018 Jan 1; 105 (1): 75-85.

BackgroundTriple-negative breast cancer (TNBC) is prone to metastasis and has a poor prognosis, with lower survival rates than other breast cancer subtypes. MicroRNAs have recently emerged as powerful regulators of cancer processes and become a promising target in cancer therapy.MethodsExpression of miR-128 was examined in invasive ductal breast cancer, and its relationship with clinicopathological features analysed. A series of in vitro and in vivo experiments were performed to investigate the function and mechanism of miR-128 in the development of invasive ductal breast cancer.ResultsA cohort of 110 women with TNBC and 117 with non-TNBC were included in the study. In multivariable Cox regression analysis, overall and disease-free survival were significantly associated with lymph node metastasis, histological grade and molecular subtype. Subgroup analysis showed that low expression of miR-128 correlated with shorter overall and disease-free survival in TNBC (P < 0·001), and shorter overall but not disease-free survival in non-TNBC. In addition, miR-128 was able to inhibit glucose metabolism, mitochondrial respiration and proliferation of TNBC cells. These effects were consistent with miR-128 targeting inhibition of the insulin receptor and insulin receptor substrate 1.ConclusionMiR-128 might be a prognostic marker and possible molecular target for therapy in patients with TNBC.© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

46 keywords...

hide…